Russian COVID vaccine: Dr Reddys likely to submit Sputnik light trial data to DCGI in November
New Delhi: Dr. Reddy's Laboratories Ltd is expected to submit Phase 3 trials data of single-dose Russian COVID-19 vaccine Sputnik Light to the Indian drug regulator next month, even as the city-based firm is getting ready to conduct trials of the jab in 2 to 18-year-old children in two cohorts.
Deepak Sapra CEO – API and Services Dr. Reddy's said the drugmaker is in discussions with the Drug Controller General of India to conduct trials on introducing Sputnik V as a booster dose.
He also said Dr. Reddy is trying to engage in discussions with the Centre for Sputnik V Government supplies even as the company sees "softness" in the off-take of the vaccine in the private sector.
"As far as Sputnik Light is concerned we are in the midst of our clinical trials and we expect that we can update post our submission to the DCGI in November.
As far as Sputnik as a booster dose is concerned, we have finalized our protocol. We are in discussions with DCGI for initiating the trials for Sputnik booster dose," Sapra said in a virtual press conference.
Read also: COVID-19: WHO continues to assess Sputnik V vaccine
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.